Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31.

View in: PubMed

subject areas

Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Arteries
Bevacizumab
Clinical Trials, Phase III as Topic
Double-Blind Method
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Prednisone
Prognosis
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Survival Rate
Taxoids
Thromboembolism
Venous Thromboembolism

authors with profiles

Mark J. Ratain